Summary
Cardinal Health Inc. reported a strong first quarter of fiscal year 2026, with total revenue climbing 22% year-over-year to $64.0 billion. This growth was primarily driven by a significant increase in pharmaceutical and specialty solutions sales, fueled by both existing and new customers, alongside contributions from strategic acquisitions. Non-GAAP operating earnings saw a substantial 37% increase, reflecting improved profitability from recent MSO platform acquisitions and strong performance in branded and specialty pharmaceuticals. The company announced a significant move with the agreement to acquire Solaris Health for approximately $1.9 billion, a strategic expansion into the urology MSO space. While this acquisition will be financed through debt and cash, it underscores Cardinal Health's commitment to expanding its specialized healthcare services. Despite increased interest expenses related to new debt financing, the company's diluted EPS also showed healthy growth, with non-GAAP diluted EPS increasing by 36%.
Financial Highlights
49 data points| Revenue | $64.01B |
| Cost of Revenue | $61.69B |
| Gross Profit | $2.32B |
| SG&A Expenses | $1.46B |
| Operating Income | $668.00M |
| Interest Expense | $80.00M |
| Net Income | $450.00M |
| EPS (Basic) | $1.89 |
| EPS (Diluted) | $1.88 |
| Shares Outstanding (Basic) | 238.00M |
| Shares Outstanding (Diluted) | 239.00M |
Key Highlights
- 1Total revenue increased by 22% to $64.0 billion for the first quarter of fiscal year 2026, driven by pharmaceutical and specialty pharmaceutical sales growth.
- 2Non-GAAP operating earnings surged by 37% to $857 million, demonstrating enhanced profitability from acquisitions and core business performance.
- 3Acquisition of Solaris Health for approximately $1.9 billion announced, strengthening the company's position in specialized healthcare services.
- 4GAAP operating earnings grew 18% to $668 million, benefiting from the acquisition of MSO platforms and Advanced Diabetes Supply Group (ADS).
- 5Non-GAAP diluted EPS rose by 36% to $2.55, reflecting strong underlying operational performance.
- 6The company is managing its liquidity effectively, with cash and equivalents increasing to $4.6 billion and no outstanding balances on its commercial paper or revolving credit facilities as of quarter-end.
- 7Capital deployment included $375 million for share repurchases and $129 million for dividends, indicating a commitment to shareholder returns.